Transcat, Inc. (NASDAQ:TRNS) Receives $130.25 Average Target Price from Analysts

Transcat, Inc. (NASDAQ:TRNS) has been assigned an average recommendation of “Hold” from the five analysts that are currently covering the company, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $111.50.

A number of research analysts recently issued reports on TRNS shares. HC Wainwright decreased their price target on shares of Transcat from $126.00 to $106.00 and set a “buy” rating for the company in a research note on Wednesday. Oppenheimer downgraded shares of Transcat from an “outperform” rating to a “market perform” rating in a research note on Wednesday. Craig Hallum raised their price target on Transcat from $113.00 to $125.00 and gave the company a “buy” rating in a research note on Thursday, December 12th. StockNews.com upgraded Transcat from a “sell” rating to a “hold” rating in a report on Tuesday. Finally, Northland Securities reissued a “market perform” rating and set a $85.00 target price (down previously from $110.00) on shares of Transcat in a research report on Wednesday.

Institutional Trading of Transcat

Large investors have recently made changes to their positions in the company. Sei Investments Co. grew its position in Transcat by 47.0% during the 2nd quarter. Sei Investments Co. now owns 7,805 shares of the scientific and technical instruments company’s stock worth $934,000 after purchasing an additional 2,495 shares during the last quarter. Marshall Wace LLP grew its holdings in shares of Transcat by 59.4% during the second quarter. Marshall Wace LLP now owns 8,267 shares of the scientific and technical instruments company’s stock worth $989,000 after buying an additional 3,080 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in Transcat by 8.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,312 shares of the scientific and technical instruments company’s stock valued at $396,000 after acquiring an additional 263 shares during the period. Diversified Trust Co increased its position in Transcat by 34.6% in the 3rd quarter. Diversified Trust Co now owns 3,985 shares of the scientific and technical instruments company’s stock valued at $481,000 after acquiring an additional 1,025 shares during the period. Finally, Annex Advisory Services LLC raised its stake in Transcat by 61.4% during the 3rd quarter. Annex Advisory Services LLC now owns 16,568 shares of the scientific and technical instruments company’s stock valued at $2,001,000 after acquiring an additional 6,304 shares during the last quarter. 98.34% of the stock is owned by institutional investors and hedge funds.

Transcat Stock Up 4.4 %

Transcat stock opened at $76.71 on Tuesday. The company’s 50 day moving average is $103.79 and its two-hundred day moving average is $114.55. The firm has a market cap of $705.73 million, a PE ratio of 38.74 and a beta of 0.71. Transcat has a 52-week low of $73.37 and a 52-week high of $147.12.

Transcat (NASDAQ:TRNS) last released its earnings results on Monday, January 27th. The scientific and technical instruments company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.38 by $0.07. Transcat had a return on equity of 7.36% and a net margin of 6.63%. During the same quarter in the previous year, the business posted $0.56 earnings per share. On average, equities research analysts anticipate that Transcat will post 2.44 earnings per share for the current fiscal year.

About Transcat

Transcat, Inc provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services.